Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market - Wikidata - wikimedia - TriplyDB

Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market

Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market

http://www.wikidata.org/entity/Q34529140

about

Pharmaceutical strategic purchasing requirements in Iran: Price interventions and the related effective factors.Assessing the Factors Associated With Iran's Intra-Industry Trade in Pharmaceuticals.A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran.Comprehensive assessment of health education and health promotion in five non-communicable disease demonstration districts in China: a cross-sectional study.Perceptions, experiences and expectations of physicians regarding the role of pharmacists in low-income and middle-income countries: the case of Tehran hospital settings.Determinants of Iran's BilateralIntra-industry Trade in Pharmaceutical Industry.

P2860

Q36646720-60254FD6-1FA3-4520-8D42-5C1557D8CB9E Q39366031-A80913BB-92FF-4B3C-89ED-B45B58E818C7 Q39366459-18575DDE-ADBD-4BCD-9F49-E4D215AAA1C4 Q47761703-E427EB11-1496-4BD6-B6A0-CD744B6964F2 Q50115851-9E44127E-D138-4548-9F40-6C054C00D01E Q55316944-AB9957DB-9DBA-4542-93E8-DB65205C221D

P2860

Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market

http://www.wikidata.org/entity/Q34529140

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Identifying and prioritizing i ...... nce from pharmaceutical market

@ast

Identifying and prioritizing i ...... nce from pharmaceutical market

@en

Identifying and prioritizing i ...... nce from pharmaceutical market

@nl

type

label

Identifying and prioritizing i ...... nce from pharmaceutical market

@ast

Identifying and prioritizing i ...... nce from pharmaceutical market

@en

Identifying and prioritizing i ...... nce from pharmaceutical market

@nl

prefLabel

Identifying and prioritizing i ...... nce from pharmaceutical market

@ast

Identifying and prioritizing i ...... nce from pharmaceutical market

@en

Identifying and prioritizing i ...... nce from pharmaceutical market

@nl

P1433

Q34529140-14E23380-9CC7-4036-A208-E6DDD3247EAC

P1476

Q34529140-B20ABE49-CD7D-4D62-8E2F-95553C025FBE

P2093

Q34529140-880793DA-5431-492B-BC51-5BCC32FB0EC8

Q34529140-A5B7FFFE-C6C9-4F2F-9D20-0FF5E14F265C

Q34529140-B0FF772F-4119-4A81-8895-759AD39CB294

Q34529140-FE458BB2-14C7-4E37-AF52-F8A6D49F710D

P2860

Q34529140-101A3F96-C90A-44A7-BEDA-44E02937FDDE

Q34529140-143178EE-C8BD-4DEF-94B0-F86D4864B004

Q34529140-221FCE07-BAF5-4E1B-A3A4-B7421B358850

Q34529140-2BECB665-369C-4789-A1AB-8ED36B9B12C0

Q34529140-6AEDB19B-8AAE-477B-B5D7-9F8A3BCC8656

Q34529140-6D9539DA-025C-4CD6-B03E-14DB6A67D0DE

Q34529140-7B1557AF-D70B-4BDF-9C5B-52E3232F8464

Q34529140-AA2FBB85-769E-4A8A-98C2-B835CC0BDD76

Q34529140-EA1E3C05-D4AD-4904-9C1E-0CB855322AC1

P2888

Q34529140-1E6C08D2-531D-458F-A540-80B8E556BF1C

P304

Q34529140-556D61A4-7DB9-4A86-9E49-EACB6A419A31

P31

Q34529140-DD14D143-77FA-40D1-9484-137EEC759C32

P356

Q34529140-D3F5CEED-245F-4247-8296-96A10C3E836E

P407

Q34529140-035009BC-A6BA-42D0-92FA-C70183DE1C5C

P433

Q34529140-8AAA81A0-6F88-4363-B71C-1FE91EA113D4

P478

Q34529140-5F58F411-860B-44CB-AAD0-3221A83EE215

P50

Q34529140-4F647659-567A-4680-BB15-DB4EB1BE9D30

P577

Q34529140-E1E83DFD-DDEF-4DEC-8D39-282D0D37202C

P5875

Q34529140-9487DB4C-4DAD-4D73-9BD4-1D2002B41AE9

P6179

Q34529140-B4436465-B6B7-432B-93B0-8C6F07C5D5D5

P698

Q34529140-54999BEE-7A42-4FF1-997D-3087F0824553

P932

Q34529140-D76E4AE2-1401-49C3-B569-AE3D45685348

P356

2008-2231-22-35

P1433

P1476

Identifying and prioritizing i ...... nce from pharmaceutical market

@en

P2093

Ahmad Baratimarnani

http://www.w3.org/2001/XMLSchema#string

Gholamhossein Mehralian

http://www.w3.org/2001/XMLSchema#string

Hamid Reza Rasekh

http://www.w3.org/2001/XMLSchema#string

Hosein Shabaninejad

http://www.w3.org/2001/XMLSchema#string

P2860

The price of innovation: new estimates of drug development costs

The value of improving the productivity of the drug development process: faster times and better decisions

Can the pharmaceutical industry reduce attrition rates?

Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries

Situation analysis of R & d activities: an empirical study in Iranian pharmaceutical companies

Pharmaceutical supply chain risks: a systematic review.

Lessons from 60 years of pharmaceutical innovation.

The importance of being first: evidence from Canadian generic pharmaceuticals.

A comparative analysis of generics markets in five European countries

P2888

2008-2231-22-35

P304

35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2008-2231-22-35

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Arash Rashidian

P577

2014-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261442265

http://www.w3.org/2001/XMLSchema#string

P6179

1044260752

http://www.w3.org/2001/XMLSchema#string

P698

24708770

http://www.w3.org/2001/XMLSchema#string

P932

4234990

http://www.w3.org/2001/XMLSchema#string